Genomics and Transcriptional Core

Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center, Torrance CA

Investigators

Abstract

PROJECT SUMMARY This Program Project “Deciphering Immunopathogenesis of MUCORmycosis to ADVANCE Risk stratification, Diagnosis and Management of the Disease (MUCOR-ADVANCE)” aims to expand our understanding of host and pathogen interactions that determine the outcome of mucormycosis infections and develop innovative diag- nostic and therapeutic strategies. The Genomics/Transcriptomics Core based at the University of Maryland Institute for Genome Sciences (IGS) is a central and vital component of this P01 proposal. The Gen/Tr Core will provide comprehensive, high-throughput transcriptome and genome sequencing and analysis for the three in- terconnected research projects focused on understanding various aspects of mucormycosis. The core's objec- tives are organized into three specific aims. In Aim 1, we will use state-of-the-art single-cell RNA-seq and dual- species bulk RNA-seq to study host-pathogen interactions during Mucormycosis in several experimental (in vivo and in vitro) contexts. In Aim 2, we will use of state-of-the-art long read DNA sequencing to enhance genome annotation and generate several reference genomes for each major genera of Mucorales. The goal is to generate high-quality genome sequences of Mucorales isolates and improve existing annotations for comprehensive in- terpretation of RNA-seq and comparative genomics analyses. Aim 3 will ensure proper collection, organization, storage and dissemination of all raw sequencing data and processed data. The Gen/Tr Core is an essential element of this program project that will provide sequencing-based technological development to support the high-impact, translational, hypothesis-driven and hypothesis-generating research in all projects. Application of these techniques will provide novel insights into interactions between Mucorales and the, thus revealing funda- mental principles about MCM and identifying novel avenues for improved management of the disease (e.g., prognostic biomarkers).